Beschreibung
This is a comprehensive textbook addressing the unique aspects of drug development for ophthalmic use. Beginning with a perspective on anatomy and physiology of the eye, the book provides a critical appraisal of principles that underlie ocular drug product development. The coverage encompasses topical and intraocular formulations, small molecules and biologics (including protein and gene therapies), conventional formulations (including solutions, suspensions, and emulsions), novel formulations (including nanoparticles, microparticles, and hydrogels), devices, and specialty products. Critical elements such as pharmacokinetics, influence of formulation technologies and ingredients, as well as impact of disease conditions on products development are addressed. Products intended for both the front and the back of the eye are discussed with an eye towards future advances.
Autorenporträt
Seshadri Neervannan, Ph.D., Chief Operating Officer, Tarsus Pharmaceuticals Inc. is a distinguished thought leader and an expert in global drug development. His expertise spans a broad range of novel therapeutic agents beginning from their discovery through commercialization. He is focused on innovation, processes, and strategies, and he has a demonstrated record of securing multiple global product approvals in eye care and other therapeutic areas. Spanning over two decades in R&D, leading various product development functions, he has developed many drug products including topical ophthalmic preparations, intraocular sustained release injectables, dermal products, drug-device combination products, oral dosage forms and parenteral injectables for small molecules and biologics. He received his Ph.D. in Pharmaceutical Chemistry from the University of Kansas. Uday B. Kompella, Ph.D., Professor of Pharmaceutical Sciences, Ophthalmology, and Bioengineering and Co-director of the Colorado Center for Nanomedicine and Nanosafety the University of Colorado, is an expert in ocular drug delivery and development. He is a Co-founder of Ocugen, Inc., a public company focused on developing novel biologics for treating eye diseases. Dr. Kompella is a Fellow of the American Association of Pharmaceutical Scientists and the Association for Research in Vision and Ophthalmology. Dr. Kompella is a recipient of the Distinguished Scientist Award and Distinguished Teacher Award at the University of Nebraska Medical Center; Deans Mentoring Award and Innovations in Science Award at University of Colorado Anschutz Medical Campus; and Undergraduate Alumni Teaching Excellence Award at Auburn University. He is also a recipient of the ARVO Foundation for Eye Research/Pfizer Ophthalmics/Carl Camras Translational Research Award in Ophthalmology. Dr. Kompella has extensive experience as an editor of scientific journals, including Expert Opinion on Drug Delivery (Editor-in-Chief, 10 years), Pharmaceutical Research (Editor, 16 years), Journal of Ocular Pharmacology and Therapeutics (Associate Editor, 10 years), and Clinical Research and Regulatory Affairs (Editor, 4 years). Dr. Kompella obtained his Ph.D. in Pharmaceutical Sciences from the University of Southern California.
Herstellerkennzeichnung:
Springer Verlag GmbH
Tiergartenstr. 17
69121 Heidelberg
DE
E-Mail: juergen.hartmann@springer.com
